Antonio Passaro’s top 10 selection with explanation, among the lung cancer abstracts from ASCO24

Antonio Passaro, shared a post on X:

”ASCO24 is ready to start soon! Here, my top 10 selection with explanation, among the lung cancer abstracts.

The LAURA study is poised to make history with its straightforward design and strong positive results on the horizon! This crucial trial may confirm a new SoC and highlight the need for advancements in Osi-resistant disease.

The ADRIATIC study might finally highlight a new SoC in limited-stage SCLC after a long (too long) wait. We’ll need to see the results to understand the magnitude of its clinical impact, but we’re ready to move beyond chemo-only treatment here too…

The KRYSTAL-12 study is highly anticipated for its potential direct and indirect impacts. Following the CodeBreak-200 results, this study will enhance our understanding of the biology and clinical applications of these first-generation KRAS inhibitors.

ADC yes or ADC no… Great expectations with mixed results. There’s excitement, but also skepticism! Very curious…

After MARIPOSA-2, the second bispecific antibody in the OSI-resistant setting. We’re still carrying chemotherapy with us, but the results (though only from an Asian cohort) are intriguing and open new horizons in NSCLC.

Simply, an important and big step forward that will revolutionize the future of treating EGFR-mutated NSCLC.

Improving our understanding of high risk patients, affected by EGFR-mutant NSCLC. An important analysis!

The COVID-19 pandemic revolutioned the clinical management of patients affected by lung cancer! Here, a piece of knowledge that will definitively change our vision and perspective.

Long-term PFS analysis is an endpoint that fills me with enthusiasm for the progress of medicine. It’s a revolution in favor of our patients, where the magnitude of clinical benefit continues to advance.

We need dedicated studies for NSCLC with brain involvement, especially for EGFR-mutated disease. Here, a very interesting study with amivantamab plus lazertinib.”

Source: Antonio Passaro/X

Antonio Passaro MD PhD, a medical oncologist at the European Institute of Oncology in Milan, specializes in lung cancer research and treatment. he focuses on developing new therapies, including immunotherapy, and identifying reliable biomarkers for non-small cell lung cancer (NSCLC). Dr. Passaro leads lung cancer trials, evaluates therapeutic efficacy and safety. Authoring over 100 peer-reviewed papers, he also holds editorial positions and key roles in societies like ESMO and AIOM.